Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders

DOI: 10.1158/2159-8290.CD-RW2019-183 Published January 2020
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major Finding: Genomic analysis identified previously unknown potential histiocytosis-driving mutations.

  • Concept: In a set of twins with histiocytosis, a CSF1R-mutant yolk-sac precursor was the disease originator.

  • Impact: Patients with histiocytoses treated according to the newly defined mutations exhibited responses.

The development of histiocytoses, clonal hematopoietic disorders of unclear cellular origin, is poorly understood, and therapeutic targets have generally been limited to BRAF and MEK, two kinases thought to drive many of these disorders. In a genomic analysis of 270 patients with various histiocytoses, Durham, Rodrigo, Picarsic, and colleagues identified a previously unknown set of potential driver mutations in genes encoding receptor tyrosine kinases, including activating mutations in CSF1R (encoding CSF1R, also known as M-CSF) and rearrangements in RET and ALK. In one case, whole-exome sequencing of tissue samples from one-year-old monozygotic, monochorionic, diamniotic twins with the histiocytic disorder systemic juvenile xanthogranuloma revealed identical in-frame deletions in CSF1R in skin lesions, but not in blood or fingernails. The presence of identical CSF1R mutations in disease lesions but not blood or fingernails of the twins supports the idea that a CSF1R-mutant extra-embryonic yolk-sac precursor was the originator of the tumors. This finding aligns with the results of a recent mouse study and does not support the alternative explanation that the origin of the malignant clone was a bone marrow–derived myeloid cell that arose in one twin and spread to the other through vascular anastomoses. In addition to identifying a potential developmental origin for a histiocytic disorder, the group tested whether the presence of certain potential driver mutations was predictive of response to corresponding drugs. Notably, substantial and sustained responses were seen in patients positive for the BICD2–BRAF, KIF5B–ALK, or NCOA4–RET rearrangements treated with the MEK1/2 inhibitor trametinib, the ALK inhibitor crizotinib, or the RET inhibitor selpercatinib, respectively. These results highlight the potential value of genomic analysis in patients with treatment-refractory histiocytoses and provide preliminary evidence supporting treatments that may be of value in patient populations bearing specific types of mutations. Additionally, further investigation to determine whether the developmental origin of other histiocytic disorders matches that described here for systemic juvenile xanthogranuloma would be of interest.

Durham BH, Rodrigo EL, Picarsic J, Abramson D, Rotemberg V, De Munck S, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 2019;25:1839–42.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 10 (1)
January 2020
Volume 10, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders
Cancer Discov January 1 2020 (10) (1) 11; DOI: 10.1158/2159-8290.CD-RW2019-183

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders
Cancer Discov January 1 2020 (10) (1) 11; DOI: 10.1158/2159-8290.CD-RW2019-183
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Mutations

  • Frameshifts in Microsatellite-Unstable Tumors Create Shared Neoantigens
  • Somatic Copy-Number Alterations Occur in the Tumor Microenvironment
  • Genomic Lesions Unrepaired at Mitosis Affect Clonal Evolution in Cancer
Show more Mutations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement